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Antimicrobial peptides (AMPs) are an ancient group of molecules
that are expressed in many species ranging from bacteria to
humans. At least 1200 naturally-occurring AMPs have been
identified which display considerable diversity in their primary
sequences, lengths, structures, and biological activities (Wang
et al., 2009). Generally speaking, these peptides have been studied
due to their ability to directly kill medically important-microbes.
Indeed, the increased demand for novel anti-infective therapies
(due to the spread of drug-resistant bacteria) has likely con-
tributed to the expansion of this field of research. However, there
has been a definite change of focus in AMP research in light of the
recent recognition of the regulatory functions of these molecules
in the innate immune system. This has opened up the excit-
ing possibility of developing novel antimicrobial therapies that
centre on boosting host immunity rather than direct microbial
killing (Zhang and Falla, 2010). In this volume, with empha-
sis on emerging technologies, mechanism of action studies and
roles in disease, we aim to consolidate some of these develop-
ments and stimulate discussion on the therapeutic potential of
these important molecules.
The first three articles demonstrate how knowledge of AMP
structure and amino acid composition is guiding rational peptide
design strategies aimed at improving the therapeutic potential of
these molecules. Mishra and Wang describe the development of
a comprehensive AMP database that is enabling us to link amino
acid composition with specific peptide activities (e.g., antibacte-
rial, antifungal, antiviral, antiparasital, insecticidal, spermicidal,
anticancer, etc.). The article suggests how this information may
be used to develop novel peptides with a desired activity. Next,
Scorciapino and Rinaldi discuss how knowledge of the amino acid
sequence of naturally-occurring AMPs can be used to dictate the
design of antimicrobial peptidomimetics. The authors note that
by retaining the biological activity of natural AMPs and improv-
ing their pharmacokinetic properties, these novel molecules may
allow systemic use of AMPs to treat microbial infections. The
third article by Devocelle describes how conjugation of AMPs to
targeting moieties can improve delivery to their desired site of
action and reduce potential off-target effects. It is clear that the
complementary approaches described in these three articles will
play an important part in making therapeutic AMPs a reality.
The next two articles describe different, but equally power-
ful, approaches that may be used to probe the biological func-
tions of AMPs. The development of various “–omics” (genomics,
transcriptomics, proteomics, and others) technologies has truly
revolutionised biological research. In this regard, Plichta et al.
discuss how the integration of various—omics datasets can help
us to understand the role of AMPs in varied contexts from resolu-
tion of infections, improvement of prognosis for cancer patients
to early detection of transplant rejection. The fifth article by
Munoz and Read highlights the use of live cell imaging to study
AMP function. With emphasis on the various approaches that
may be used to label AMPs, this article demonstrates the central
role live cell imaging continues to play in the elucidation of AMP
function.
The next six articles in this research topic cover recent advances
in our understanding of the biological role of AMPs and their
mechanism(s) of action. Brender et al. examine the role of
cholesterol in dictating the selectivity of AMPs for microbial
membranes. Defining the role of cholesterol in AMP-mediated
cytotoxicity is important, especially if AMPs are to be used thera-
peutically. Melo and Castanho discuss the various experimental
approaches that may be used to answer this very question. By
comparing the use of bacterial membranes with model liposomal
membranes, they illustrate the importance of physiological rele-
vance in experimental design. The next two articles in this series
illustrate how helminths express AMP homologues that are func-
tionally adapted to either a free-living or parasitic lifestyle. For
example, Pujol et al. describe the array of AMPs expressed by the
model nematode Caenorhabditis elelgans and how they serve to
protect the worm against attack by fungi in the free-living envi-
ronment. Next, Cotton et al. probe the role of AMP homologues
that are secreted by medically-important parasitic worms. This
interesting family of molecules may hold the key to the evolution
of immunomodulatory function in AMPs. In the following two
articles, Ulm et al. and Choi and Mookherjee discuss advances
in our understanding of the molecular mechanisms by which
members of these major AMP families influence immune cell
function.
The final two articles in the volume cover the role of AMPs
in disease resolution and the outlook for their therapeutic use
in humans. The article by David describes how AMPs may fill a
gap in our existing therapeutic repertoire. David builds the case
for the use of polymyxins to treat Gram-negative sepsis, a condi-
tion for which there is currently no single effective therapeutic
approach. The article by Berditsch et al. concludes the volume
and describes how, perhaps surprisingly, AMPs can stimulate bac-
terial survival mechanisms leading to persistent infections. This
article highlights the importance of understanding howmicrobial
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populations respond to exposure to AMPs before they can be used
in the clinic.
In summary, by inviting opinion articles from leading AMP
researchers, the aim of this volume was to highlight recent
advances in our understanding of the roles of these important
molecules. We also hope that the articles compiled will stimulate
discussion and further research in this area so that the therapeutic
potential of AMPs may be realised.
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